Singapore-based biotechnology company Mirxes is piloting an AI-driven clinical assistant aimed at improving how healthcare professionals access and use complex diagnostic information.
The assistant is designed to handle scientific and product-related queries in near real time, helping clinicians navigate large volumes of medical data more efficiently. The system is aimed at reducing response times, easing clinician workload, and supporting more informed decision-making in clinical settings.
“Earlier cancer detection depends on precision, speed, and trust in the information clinicians receive,” said Dr Zhou Lihan.
“By giving clinicians fast access to accurate, up-to-date information, we can reduce that burden and allow them to focus more on direct patient care and clinical decision-making,” he added.
Addressing clinical knowledge gaps
The AI assistant is built using Oracle AI Database and Oracle Cloud Infrastructure (OCI) Enterprise AI to draw on curated medical literature, scientific research and internal documentation, delivering consistent responses to clinician queries on demand. This helps reduce reliance on manual processes that can delay access to critical information.
It also introduces agentic capabilities, allowing the system to route product-related questions and feedback to relevant teams automatically, streamlining internal workflows without removing clinicians from the decision-making process.
Importantly, clinical judgement remains fully with healthcare professionals, with the system designed to operate within regulatory and data privacy requirements.
Rather than a broad AI overhaul, Mirxes’ approach focuses on a targeted use case to improve knowledge delivery in clinical environments where speed and accuracy are critical.
The system uses techniques such as semantic search and retrieval-augmented generation (RAG) to interpret queries and return contextually relevant answers, helping clinicians access insights faster, particularly in time-sensitive scenarios like early disease detection.
Founded in 2014, Mirxes is a key player in RNA-based diagnostics in Asia-Pacific. The AI assistant represents a step towards scaling its clinical support capabilities as it expands access to early cancer detection tools.
